We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.

Community Guidelines: bit.ly/2MgAcio

ADC Therapeutics

Viela Bio

Cellular Biomedicine Group

Moderna

FibroGen

Innate Pharma

Nektar Therapeutics

PhaseBio Pharmaceuticals

Rani Therapeutics

AstraZeneca

Join us live at the London Stock Exchange’s Market Open Ceremony with our CEO Pascal Soriot and our leadership team as we announce our FY and Q4 2023 Results and mark 25 years of pioneering science.

We are pleased to report 2023 was another year of double-digit growth and scientific progress, with investments in exciting areas of science that lay the foundations for continued long-term success. 

This year we are excited to celebrate our 25th anniversary with our teams around the world. Thank you for unlocking the power of what science can do for people, society and the planet. 

#AZN #WhatScienceCanDo

Our Full Year and Q4 2023 Results announcement will be available from 07:00 GMT on Thursday 8 February 2024. 
 
Join the accompanying webcast for investors and analysts at 11:45 GMT – you can register to attend here: https://lnkd.in/eBerW6Vc

Join us live tomorrow at the London Stock Exchange’s Market Open Ceremony as we announce our FY and Q4 2023 Results and mark 25 years of pioneering science. 

Set up a reminder to watch here: https://learn.az/6042V3qhg

Innovations in cell therapy are advancing the treatment of some blood cancers for patients. However, there are challenges in using the therapy to treat other types of cancer.  

Susan Galbraith, EVP of Oncology R&D, shares her thoughts on how we can expand the potential of cell therapies to reach more people impacted by cancer. https://learn.az/6049psAnh 

World Economic Forum 
#WorldCancerDay #CloseTheCareGap

Congratulations to Prof Sir Mene Pangalos, who has received the prestigious BioIndustry Association (BIA) Lifetime Achievement Award. The award celebrates not only Mene’s career, but recognises the incredible impact scientists have on patients and society. Learn more: https://learn.az/6047T0fpJ 

#WhatScienceCanDo

Providing young people access to quality science, technology, engineering and mathematics (#STEM) education can inspire them to pursue their interests and explore potential careers in STEM.

Our global programmes, supported by our four key pillars, foster inclusive environments dedicated to inspiring the next generation of scientists, researchers and innovators. 

Learn more: https://learn.az/6049T5GW1

We’re taking action to protect and restore ecosystems by lowering the environmental footprint of healthcare whilst investing in nature and biodiversity. 

As part of our commitment to following the science and to transparently communicating our progress on how we are protecting biodiversity, this week, we became an Early Adopter of the Taskforce on Nature-related Financial Disclosures (TNFD). 

TNFD will support us in identifying and assessing our nature-related dependencies, impacts, risks, and opportunities.

Discover more here: https://learn.az/6047rtPlt

#TNFDEarlyAdopter #TNFD #WEF24

Health must be front and centre of tackling the climate crisis. By taking a health-centred approach, we can improve both the sustainability and resilience of our health systems. 

We co-hosted a discussion on this critical topic with Vanessa Kerry, MD MSc from the World Health Organization and Seed Global Health, and Devex on the practical steps needed to strengthen financing of health systems in the face of climate change.

Expanding the resources necessary to drive transformative action is urgent for the health of people, society and our planet. #ItStartsWithHealth #WEF24

We’re proud to have launched a renewable power agreement in China together with Lonza, Novartis, Novo Nordisk, Roche and Envision Energy. 

Convened through the The Sustainable Markets Initiative Health Systems Task Force, this milestone agreement is the first time the pharmaceuticals sector has collaborated on green power in China, and it’s set to achieve annual CO2e savings of around 120,000 tonnes. That’s the equivalent of taking 25,000 cars off the road.
 
We can achieve more when we work in partnership. 
 
Learn more: https://lnkd.in/eTVhjeqe

Dosage Reminder

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

SSL by Default

Apple Mobile Web Clips Icon

Google Font API

HSTS

Google Maps

Content Delivery Network

LetsEncrypt

CEO/Chief Data Strategist

Ade Ajibola

Process Capability Owner

Alan Fieldhouse

Global Commercial IT Business Performance Manager

Andrea Pagano

Vice President Finance & CFO International

Ankush Nandra

Chief Medical Officer

Ann Taylor

Sr. Engineer & System Owner

Antoinette Liggians

Area CFO Central Eastern Europe & Baltics

Anu Kumar

VP IT & Chief Data Officer

Brian Dummann

Assistant General Counsel and Head of Legal Operations

Cara Kearney

Chief Digital Officer & CIO

Cindy (she

Nazneen Rahman

Pingping Ni

Pascal Soriot

Tony Mok

Bruce Burlington

Cornelia Bargmann

Baroness Vadera

Leif Johansson

Bonnie Cheuk

Senior Business and Digital Transformation Leader

Laura Bonifacio

Senior Global Clinical Operations Program Director

Jenny Leo

Vice President Human Resources China

Nicholas Darton

Principal Scientist

Carl Sidenvall

Project Manager

Michel Vandenberghe

Director

Karan Arora

Head, Commercial Digital & Innovation, Global Vice President

Sofía Calderón Flores

Procurement Team Manager

Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes.

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

Moderna Therapeutics is a biotechnology company that specializes in vaccines and drug development.

Innate Pharma is a biopharmaceutical company developing immunotherapy drug candidates for the treatment of cancer and inflammatory diseases.

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.

FibroGen uses its expertise in CTGF and HIF biology to discover, develop, and commercialize novel therapeutics.

Nektar Therapeutics develops therapeutics based on its advanced polymer conjugate chemistry technology platform.

Allegiance Health is a community-owned, locally-governed health system in Jackson, Michigan.

PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.

Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.

Cambridge Companies With More Than $1M in Revenue

Companies With More Than $100M in Revenue (Top 10K)

Investors Active in Hainan

Europe, Middle East, and Africa (EMEA) Health Care Companies (Top 10K)

AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines that make a meaningful difference in healthcare. It discovers new medicines that are designed to improve the health and quality of life of patients, offering added benefits such as reduced side effects or better ways of taking the treatment. It focuses on getting the best from every medicine it makes by exploring all the ways it can be used or improved.

Post-IPO Debt - AstraZeneca

Cambridge

Cambridgeshire

United Kingdom

Europe

AstraZeneca pleased as EU approves Fasenra for treatment of EGPA

Astrazeneca (AZN) Declines More Than Market: Some Information for Investors

Monopar Shares Surge on AstraZeneca Licensing Deal -- Update

Eccogene gets $60M from AstraZeneca; Evotec also records milestone with BMS

ASTRAZENECA : Berenberg reiterates its Buy rating

Merck unveils RSV antibody data, in bid to compete with AstraZeneca and Sanofi

AstraZeneca's Tagrisso plus Orpathys shows promising results

AstraZeneca: approved in China

Enhertu by AstraZeneca, Daiichi wins new approval in China

AstraZeneca: Alexion to present 11 summaries of its advances

United States

North America

India

Asia

Canada

Singapore

HTML5

Matomo (Formerly Piwik)

jQuery

Google Fonts

Twilio

Vimeo

Google Maps API

Facebook

Modernizr

Google Tag Manager

AstraZeneca owns MedImmune

AstraZeneca owns Entasis Therapeutics

AstraZeneca owns Astra Pharmaceuticals

Pfizer is a multinational pharmaceutical corporation that develops and produces medicines and vaccines for a wide range of medical disciplines.

Pfizer

Novartis is a Swiss multinational pharmaceutical company known for its research and development of innovative healthcare products.

Novartis

GSK, or GlaxoSmithKline, is a global healthcare company that researches, develops, and manufactures pharmaceuticals, vaccines, and consumer healthcare products.

Roche is a leading global healthcare company that focuses on pharmaceuticals and diagnostics, with a strong emphasis on personalized healthcare.

Roche

Bristol Myers Squibb is a global biopharmaceutical company that develops and delivers innovative medicines for patients with serious diseases.

Bristol Myers Squibb

Bayer is a multinational pharmaceutical and life sciences company that focuses on healthcare, crop science, and consumer health products.

Bayer

AstraZeneca plc is a British multinational pharmaceutical and biotechnology company with a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

news impact assignment basic	general	Mar 7, 2024 2:39 PM	ed60d684
public peers	general
news daily refresh	general	Sep 1, 2024 6:30 PM	d47676b0
news processing daily refresh	general	Sep 2, 2024 3:50 PM	fb56ef57
news impact assignment daily	general	Sep 2, 2024 4:45 PM	965f09c0
news processing basic	general	Mar 7, 2024 2:39 PM	6f0ab966
company summary	general	Sep 3, 2024 1:38 AM	910b977c
signals	general	Mar 7, 2024 2:39 PM	0bcf210b
crunchbase trigger	general	Oct 31, 2024 9:55 AM	b097335f
crunchbase profile	general	Oct 31, 2024 10:05 AM	a42722de
li profile	general	Mar 7, 2024 2:39 PM	e85e2d0c
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	2a80819b
peers	general	Mar 7, 2024 2:39 PM	57146e76
news basic	general	Mar 7, 2024 2:39 PM	834a7cfc
bundesanzeiger	filings	Mar 7, 2024 2:39 PM	e5567e18
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ASTRAZENECA

AstraZeneca plc

Last Close

9,969.00

21/11 16:55

Market Cap

1.88B

Beta: -

Volume Today

2.71M

Avg: -